Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during longterm follow-up

JAMA

Volumn 305, Issue 14, 2011, Pages 1460-1468

  Bartelds, Geertje M ^a   Krieckaert, Charlotte L M ^a   Nurmohamed, Michael T ^a,b   Van Schouwenburg, Pauline A ^c   Lems, Willem F ^b   Twisk, Jos W R ^b   Dijkmans, Ben A C ^b   Aarden, Lucien ^c   Wolbink, Gerrit Jan ^a,c  

^a Jan Van Breemen Research Institute   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DRUG ANTIBODY;

ADULT; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 79953906254     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.406     Document Type: Article

References (23)

1. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348 (7):601-608. (Pubitemid 36204954)
2. Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(3):711-715.
3. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66(7):921-926. (Pubitemid 46999794)
4. van Kuijk AW,de Groot M,Stapel SO, Dijkmans BA, Wolbink GJ, Tak PP. Relationshipbetweenthe clinical response toadalimumabtreatmentandserumlevels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis. Ann Rheum Dis. 2010;69 (3):624-625.
5. Lecluse LL, Driessen RJ, Spuls PI, et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol. 2010;146(2):127-132.
6. Calabresi PA, Giovannoni G, Confavreux C, et al; AFFIRM and SENTINEL Investigators. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007; 69(14):1391-1403. (Pubitemid 47511460)
7. West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, van der Woude CJ. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther. 2008;28(9):1122-1126.
8. Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis. 2010;4(4):355-366.
9. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on longterm outcome of adalimumab therapy in Crohn's disease. Gastroenterology. 2009;137(5):1628-1640.
10. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis. 2010; 69(5):817-821.
11. Bartelds GM, de Groot E, Nurmohamed MT, et al. Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study. Arthritis Res Ther. 2010;12(6): R221.
12. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis. 2007;66(suppl 3):iii2-iii22. (Pubitemid 350032626)
13. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eightjoint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38 (1):44-48.
14. Wolbink GJ, Voskuyl AE, Lems WF, et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2005;64 (5):704-707. (Pubitemid 40559296)
15. van Schouwenburg PA, Bartelds GM, Hart MH, Aarden L, Wolbink GJ, Wouters D. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients. J Immunol Methods. 2010;362(1-2):82-88.
16. Blom M, Kievit W, Kuper HH, et al. Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice. Arthritis Care Res (Hoboken). 2010;62(9):1335-1341.
17. Jamnitski A, Bartelds GM, Nurmohamed MT, et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis. 2011;70(2):284-288.
18. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007;56(9):1226-1231. (Pubitemid 47300423)
19. Krieckaert CL, Bartelds GM, Lems WF, Wolbink GJ. The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther. 2010;12 (5):217.
20. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Anti-adalimumab antibodies in rheumatoid arthritis patients are associatedwith interleukin-10 gene polymorphisms. Arthritis Rheum. 2009;60(8):2541-2542.
21. Miyasaka N; CHANGE Study Investigators. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol. 2008;18(3): 252-262.
22. Radstake TR, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009;68(11):1739-1745.
23. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 2006;54(12):3782-3789. (Pubitemid 44955878)